MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-23-2025
Integer Holdings Corporation Revenue 2011-2026 | ITGR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Integer Holdings Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.72 B | 1.56 B | 1.33 B | 1.22 B | 1.07 B | 1.26 B | 1.22 B | 1.14 B | 800 M | 688 M | 664 M | - | 646 M | 569 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.72 B | 569 M | 1.07 B |
Quarterly Revenue Integer Holdings Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 468 M | 476 M | 437 M | - | 431 M | 428 M | 408 M | - | 397 M | 400 M | 379 M | - | 343 M | 350 M | 311 M | - | 306 M | 312 M | 290 M | 269 M | 236 M | 240 M | 328 M | 326 M | 304 M | 314 M | 315 M | 303 M | 305 M | 314 M | 382 M | 390 M | 363 M | 281 M | 345 M | 360 M | 347 M | 348 M | 332 M | 170 M | 147 M | 175 M | 161 M | 177 M | 172 M | 172 M | 174 M | - | 168 M | 171 M | 148 M | 159 M | 161 M | 167 M | 159 M | 142 M | 132 M | 147 M | 149 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 476 M | 132 M | 281 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
848 M | - | - | $ 17.2 B |  USA |
 |
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | USA |
 |
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | USA |
 |
Alphatec Holdings
ATEC
|
612 M | $ 21.04 | 0.86 % | $ 3.01 B | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | USA |
 |
Apyx Medical Corporation
APYX
|
52.3 M | $ 3.5 | 1.74 % | $ 121 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
443 M | $ 9.4 | 1.08 % | $ 675 M |  Israel |
 |
Boston Scientific Corporation
BSX
|
16.7 B | $ 95.35 | -0.69 % | $ 140 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bio-Rad Laboratories
BIO
|
2.57 B | $ 302.99 | -0.5 % | $ 8.55 B | USA |
 |
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | USA |
 |
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | USA |
 |
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | USA |
 |
Bruker Corporation
BRKR
|
3.37 B | $ 47.11 | -0.84 % | $ 7.02 K | USA |
 |
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
64 M | $ 29.12 | 1.01 % | $ 246 M | USA |
 |
Abbott Laboratories
ABT
|
42 B | $ 125.29 | -0.39 % | $ 218 B | USA |
 |
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.29 | 2.49 % | $ 123 M |  France |
 |
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | USA |
 |
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M |  Canada |
 |
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | USA |
 |
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | USA |
 |
InMode Ltd.
INMD
|
358 M | $ 14.69 | -1.01 % | $ 1.17 B | Israel |
 |
IRadimed Corporation
IRMD
|
73.2 M | $ 97.28 | -0.5 % | $ 1.23 B | USA |
 |
Align Technology
ALGN
|
4 B | $ 156.15 | -1.26 % | $ 11.7 B | USA |
 |
Accuray Incorporated
ARAY
|
459 M | $ 0.82 | 2.64 % | $ 84.3 M | USA |
 |
LivaNova PLC
LIVN
|
1.25 B | $ 61.53 | -1.2 % | $ 3.34 B |  Britain |
|
LENSAR
LNSR
|
53.5 M | $ 11.63 | - | $ 134 M | USA |
 |
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
31.4 M | $ 13.68 | 0.81 % | $ 370 M | USA |
 |
FONAR Corporation
FONR
|
97.6 M | $ 18.56 | -0.22 % | $ 122 M | USA |
 |
AxoGen
AXGN
|
187 M | $ 32.73 | - | $ 1.45 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | USA |
 |
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.14 | -0.87 % | $ 18.4 M | USA |
 |
CONMED Corporation
CNMD
|
1.31 B | $ 40.6 | -1.31 % | $ 1.25 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
205 M | $ 17.76 | -1.11 % | $ 410 M | USA |
 |
Globus Medical
GMED
|
2.52 B | $ 87.31 | -0.68 % | $ 11.9 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 12.42 | -2.05 % | $ 956 M | USA |
 |
Aziyo Biologics
AZYO
|
24.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Myomo
MYO
|
1 B | $ 0.91 | -1.58 % | $ 6.42 M | USA |